Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells...

Related Keywords

United States ,American ,Christopherm Calabrese ,Ron Bentsur ,Astra Zeneca ,Exchange Commission ,Nuvectis Pharma Inc ,Company Contact ,Drug Administration ,American Association For Cancer Research ,Nasdaq ,Highly Synergistic Antiproliferative Activity ,Active Ingredient ,Agent Antiproliferative Activity ,Cells Resistant ,Cancer Research ,Chief Executive Officer ,Nuvectis Pharma ,Fast Track Designation ,Orphan Drug Designation ,Private Securities Litigation Reform Act ,